DR. WAYNE I LENCER, MD
Medical Practice at Longwood Ave, Boston, MA

License number

Massachusetts 45839

Professional information

Professor Of Pediatrics At Children's Hospital Boston

Position:

Professor of Pediatrics at Children's Hospital Boston, Professor at Harvard Medical School

Location:

Greater Boston Area

Industry:

Research

Work:

Children's Hospital Boston - Professor of Pediatrics Harvard Medical School since 1984 - Professor

Dr. Wayne I Lencer, Boston MA - MD (Doctor of Medicine)

Specialties:

Pediatric Gastroenterology

Address:

CHILDRENS HOSPITAL BOSTON
300 Longwood Ave, Boston 02115
(617) 355-6000 (Phone)
CHILDRENS HOSPITAL BOSTON
300 Longwood Ave, Boston 02115
(617) 355-6117 (Phone), (617) 738-7066 (Fax)

Certifications:

Pediatric Gastroenterology, 2005, Pediatrics, 1983

Awards:

Healthgrades Honor Roll

Languages:

English

Hospitals:

CHILDRENS HOSPITAL BOSTON
300 Longwood Ave, Boston 02115
CHILDRENS HOSPITAL BOSTON
300 Longwood Ave, Boston 02115
Brigham and Women's Hospital
75 Francis St, Boston 02115

Education:

Medical School
Boston Univ Sch Of Med
Graduated: 1977
Boston Medical Center
Chldns Hosp-Mass Genl Hosp

Professor Of Pediatrics At Children's Hospital Boston Professor At Harvard Medical School

Location:

Greater Boston Area

Industry:

Research

Experience:

Children's Hospital Boston (Non-Profit; 5001-10,000 employees; Research industry): Professor of Pediatrics, (-) Harvard Medical School (Research industry): Professor, (1984-Present)

Wayne Isaac Lencer, Boston MA

Specialties:

Pediatrics, Pediatric Gastroenterology, Gastroenterology

Work:

Children's Hospital
300 Longwood Ave, Boston, MA 02115

Education:

Boston University(1977)

Receptor Specific Transepithelial Transport Of Therapeutics

US Patent:

6485726, Nov 26, 2002

Filed:

Jul 24, 1998

Appl. No.:

09/122144

Inventors:

Richard S. Blumberg - Chestnut Hill MA
Neil E. Simister - Wellesley MA
Wayne I. Lencer - Jamaica Plain MA

Assignee:

The Brigham and Womens Hospital, Inc. - Boston MA
Brandeis University - Waltham MA

International Classification:

A61K 3900

US Classification:

4241781, 4241851, 4241921, 4241931, 4242771

Abstract:

The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

Central Airway Administration For Systemic Delivery Of Therapeutics

US Patent:

2004006, Apr 1, 2004

Filed:

Jul 17, 2003

Appl. No.:

10/622108

Inventors:

Richard Blumberg - Chestnut Hill MA, US
Wayne Lencer - Jamaica Plain MA, US
Neil Simister - Wellesley MA, US
Alan Bitonti - Acton MA, US

International Classification:

C07K014/54, C07K016/46

US Classification:

530/351000, 530/391100

Abstract:

The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. In particular embodiments the conjugates are fusion proteins in which a therapeutic polypeptide is joined at its C terminal end through a peptide linker to the N terminal end of an immunoglobulin Fc gamma heavy chain, wherein the linker includes Glycine and Serine residues and is preferably 15 amino acids long. In one embodiment the fusion protein includes an interferon-alpha 2b (IFN-2b) joined at its C terminal end through a peptide linker having a sequence Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO:29) to the N terminal end of a human Fc1 heavy chain. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

Receptor Specific Transepithelial Transport Of Therapeutics

US Patent:

7547436, Jun 16, 2009

Filed:

Feb 23, 2006

Appl. No.:

11/360849

Inventors:

Richard S. Blumberg - Chestnut Hill MA, US
Wayne I. Lencer - Jamaica Plain MA, US
Neil E. Simister - Wellesley MA, US

Assignee:

The Brigham and Women's Hospital, Inc. - Boston MA
Brandeis University - Waltham MA

International Classification:

A61K 39/395, A61K 38/21

US Classification:

4241341, 424 854, 424 855, 424 856, 424 857, 4241781, 424809, 514 2

Abstract:

Methods And Products For Treating Diarrhea And Scours: Use Of Clotrimazole And Related Aromatic Compounds

US Patent:

5889038, Mar 30, 1999

Filed:

Mar 20, 1996

Appl. No.:

8/621169

Inventors:

Wayne I. Lencer - Jamaica Plain MA
Carlo Brugnara - Newton Highlands MA
Seth Alper - Jamaica Plain MA

Assignee:

Children's Hospital - Boston MA

International Classification:

A61K 3147, A61K 3144, A61K 31415, A61K 3140, A61K 31405, A61K 3138, A61K 3134

US Classification:

514396

Abstract:

A method and product for treating and preventing diarrhea and scours is provided. The method involves treating a subject who has diarrhea, or scours, or is at risk of getting diarrhea or scours with an aromatic compound of the invention. The products of the invention are a veterinary preparation of the aromatic compound of the invention and an anti-scours agent, and a pharmaceutical preparation of the aromatic compound of the invention and an anti-diarrheal agent.